Navigation Links
ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization

Company Appoints Randall St. Laurent as EVP of Commercial Operations

DENVER, March 28 /PRNewswire/ -- ARCA Discovery, Inc., a privately held company, today announced that it has changed its name to ARCA biopharma, effective immediately. In support of the commercial transformation, ARCA has appointed Randall St. Laurent as executive vice president of commercial operations.

"As we move toward the completion of our new drug application submission for bucindolol, we feel 'ARCA biopharma' better reflects our biological heritage in genetic targeting and focus on commercialization of pharmaceutical products for cardiovascular patients," said Richard B. Brewer, president and chief executive officer of ARCA. "At the same time, we continue to emphasize our basic research programs in molecular genetics, which are the key to our successful drug development programs."

Mr. St. Laurent brings over 20 years of cardiovascular sales and marketing experience to ARCA. Over the past six years, most recently as vice president of commercial development at Scios, a Johnson & Johnson company, where Mr. St. Laurent played a pivotal role in the successful launch and commercialization of Natrecor, a recombinant form of BNP for acute heart failure. During his tenure at Scios he created and built a sales organization from the bottom up.

"At this critical juncture, we welcome Randy as an important addition to our team as we transition to a commercial organization. Randy's cardiovascular sales and marketing experience will be critical in bringing our lead product, bucindolol, to market, possibly as the first personalized cardiovascular medicine ever commercialized," added Mr. Brewer.

The company plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) within the next few months for its lead product candidate, bucindolol, for the treatment of chronic heart failure (HF) in patients with a specific genetic profile. ARCA plans to market bucindolol, for which it owns exclusive worldwide rights, in the U.S. through its own sales force.

Bucindolol is a next-generation beta-blocker and vasodilator that could become the first personalized, genetically-targeted cardiovascular therapy, based on substantial Phase 3 data showing that physicians could determine whether bucindolol is the right therapy for a patient with a simple genetic test.

Landmark research published in the Proceedings of the National Academies of Sciences in 2006 demonstrated that bucindolol can reduce mortality in HF patients when used as a genetically-targeted treatment. More recently, the company presented data at last November's American Heart Association annual meeting, which showed that treatment with bucindolol also helped to prevent atrial fibrillation and life threatening ventricular arrhythmia.

ARCA developed bucindolol by leveraging its proprietary technology platform combining expertise in cardiovascular pathophysiology, molecular genetics and clinical development, in a unique approach that enables the efficient identification of pharmacogenetic targets. ARCA's earlier research identified pathways affecting bucindolol response that are modulated by common genetic variations.

About ARCA biopharma, Inc.

ARCA biopharma, Inc. is a privately-held company based in Denver, Colorado focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round. For more information please visit

SOURCE ARCA Discovery, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery
2. Baby Madness is Sweeping the Nation! Forty Sets of Twins and Triplets Hit the Court in Discovery Healths BABY MADNESS: MULTIPLES
3. Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
4. New protein discovery helps researchers understand autoimmune diseases
5. Specialists in drug discovery and development convene
6. Keystone Programs for Collaborative Discovery Launch at Fox Chase
7. Natural Products Discovery and Production
8. AMD discovery: New hope for treatment of vision loss
9. Merging discovery with therapy: Second generation memory care debuts
10. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
11. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
Post Your Comments:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology: